Press Releases

Date	Title
12/7/20	Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
12/4/20	Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
11/30/20	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/25/20	Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
11/20/20	Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
11/5/20	Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
11/5/20	Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
11/2/20	Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
10/29/20	Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
10/22/20	Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics

IR Menu